Form 4: Director Acquires Caris Life Sciences Stock

Jeff L. Vacirca, a Director at Caris Life Sciences, Inc., reported the acquisition of 31,050 shares of common stock on May 11, 2026.

Summary

• Director Jeff L. Vacirca acquired 31,050 shares of Caris Life Sciences, Inc. common stock on May 11, 2026.
• The acquisition was made at a weighted average price of $16.149 per share, with individual transactions ranging from $16.13 to $16.15.
• Following this transaction, Vacirca beneficially owns 49,671 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a director's investment in the company, but it does not contain operational or financial performance data.

Positives

• Director's increased stake in the company suggests confidence in its future prospects.
• The acquisition of a significant number of shares by a director can be viewed positively by the market.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by directors, are often interpreted as a signal of management's belief in the company's intrinsic value and future growth potential within the life sciences sector.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal of confidence in the company's future.

Key Dates

Keywords

Caris Life Sciences, Form 4, SEC Filing, Insider Trading, Stock Acquisition, Director Purchase, Common Stock